Atopaxar, formerly known as E5555, is a potent and orally -active PAR-1 inhibitor.

Protease-Activated Receptor-2, amide (peptide sequence shortening: SLIGKV-NH2), an activating peptide of PAR2, is a novel, highly potent and selective agonist of protease-activated receptor-2 (PAR2) (Ki = 9.64 μM; IC50 = 10.4 μM).

ML-161 is a novel and potent allosteric inhibitor of PAR1 (proteinase-activated receptor 1) on platelets with IC50 of 0.26 μM.

AC-55541 is an agonist of protease-activated receptor (PAR) 2.

PAR-2 inhibitor is a PAR-2 signaling pathway inhibitor.

Vorapaxar sulfate, the sulfuric acid salt form of Vorapaxar (also known as SCH-530348; Zontivity), is an orally bioactive anti-platelet drug acting as a thrombin receptor protease-activated receptor (PAR-1) antagonist.

BMS-986120 (BMS986120) is a novel, potent and orally bioactive antagonist of protease-activated receptor-4 (PAR4) with the potential to be used for thrombus propagation and pathological vascular occlusion.

I-191 is a potent antagonist of protease-activated receptor 2 (PAR2).

AZ3451 is a novel and potent protease-activated receptor-2 (PAR2) antagonist with IC50 of 23 nM.

Vorapaxar (formerly SCH-530348; SCH530348; Zontivity), a new anti-platelet drug based on the natural product himbacine, is a thrombin receptor protease-activated receptor (PAR-1) antagonist that inhibits thrombin-induced platelet activation.